The pharmaceutical industry works under some of the strictest regulations of any industry in the world. Every batch record, quality review, manufacturing procedure, and approval workflow must be documented accurately with the goal of creating repeatable processes. As pharmaceutical organizations continue to move their operations to computerized systems, understanding the U.S. Food and Drug Administration’s (FDA) requirements for electronic records and electronic signatures has become the guiding principle for maintaining compliance throughout the organization’s computerized system landscape.
One of the most important regulations governing computerized system compliance in the pharmaceutical industry is FDA 21 CFR Part 11 (Part 11). Part 11 establishes the criteria under which the FDA considers electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures.
For pharmaceutical companies, CMOs, CDMOs, and biotech startups alike, understanding and applying this guidance is critical when selecting software platforms, ERP solutions, and quality management tools.
What Is FDA 21 CFR Part 11?
FDA 21 CFR Part 11 is a section of the Code of Federal Regulations created by the FDA to govern the use of electronic systems in regulated industries, like the pharmaceutical industry. The regulation applies to organizations (most commonly pharmaceuticals and manufacturing) that create, modify, maintain, archive, retrieve, or transmit electronic records related to FDA-regulated activities.
Part 11’s goal is to require that computerized systems provide the same level of integrity, security, and traceability as traditional paper-based processes.
Under FDA 21 CFR Part 11, companies must ensure that:
- Electronic records are accurate and secure
- Electronic signatures are unique and attributable to an individual
- Systems maintain detailed audit trails
- Records cannot be altered without audit trail traceability
- Access to sensitive data is controlled and restricted
- Data is retained and retrievable in a human readable format throughout required retention periods
Part 11 requirements have pushed pharmaceutical organizations toward selecting validated software solutions that can support electronic record and signature-compliant activities/processes across manufacturing, quality assurance, supply chain, and any other regulatory activities.
Why Electronic Records Matter in Pharma
The pharmaceutical industry generates a tremendous amount of documentation throughout the product lifecycle. These electronic records may include, but not limited to:
- Batch production records
- Quality control testing results
- Standard operating procedures (SOPs)
- Equipment calibration logs
- Training records
- Validation documentation
- Supplier certifications
- Inventory and lot traceability data
- Stability testing records
Historically, many organizations utilized paper-based processes for everything. However, paper systems create challenges related to storage, retrieval, version control, and audit readiness. Most of all, paper processes are more prone to human error leading to unneeded deviations.
Modern ERP and quality management systems allow pharmaceutical companies to process and store records electronically while improving operational efficiency and reducing manual errors.
The FDA recognizes the value of using computerized systems but the requirement is those systems’ electronic records to consistently maintain integrity and confidentiality at all times. This is why organizations must ensure (and continue to ensure) that their software platforms align with FDA 21 CFR Part 11 guidance.
Key Requirements for Compliant Electronic Signatures
Electronic signatures are another major component of FDA’s Part 11 compliance. Within pharmaceutical organizations, signatures are used to approve documents, release batches, verify testing, authorize deviations, and complete quality reviews (among other processes).
Under Part 11, electronic signatures must follow several key requirements to ensure security, accountability, and data integrity.
1. Unique User Identification
Each electronic signature must belong to one specific person. Shared usernames or generic logins are not compliant because they make it impossible to determine who actually performed an action.
2. Secure Authentication
Users should be required to securely log into the system. Typically, logging into the system involves utilization of a username and password. Logging into the system is required before applying electronic signatures.
3. Signature Traceability
Electronic signatures must remain permanently connected to the related electronic record. This helps prevent signatures from being copied, deleted, or reassigned without being detected.
4. Audit Trail Documentation
The system must maintain secure audit trails that track:
- Who signed the record
- When the signature was applied
- What changes were made
- Why the change was made, when applicable
5. Record Integrity
Electronic signature controls must help protect approved records from unauthorized edits or tampering.
Together, these requirements help organizations maintain strong data integrity and provide the transparency needed during FDA inspections and internal audits.
Read Also: OQ Scripts and FRS Templates for 21 CFR Part 11 Software: How to Validate Your Pharma ERP
The Importance of Audit Trails
One of the most critical aspects of FDA guidance is the requirement for audit trails. Audit trails provide a detailed and non-editable history of all activity within a regulated system.
A compliant audit trail should automatically capture:
- Record creation
- Record modifications
- User activity
- Date and time stamps
- Approval workflows
- System-generated changes
Audit trails cannot be editable by any user of the system and must remain securely preserved throughout the record retention period. When preserved, the data must be maintained in a human-readable format.
Without reliable and consistent audit trails, pharmaceutical companies will not be able to demonstrate compliance during FDA inspections or customer audits.
How FDA Guidance Shapes Software Selection
As pharmaceutical organizations evaluate ERP and software platforms, FDA guidance should play a key role in the selection process.
Most ERP systems are not designed specifically for the regulated pharmaceutical environment. Generic ERP solutions may lack features necessary for maintaining compliant electronic records and electronic signatures.
When evaluating software vendors, organizations should look for capabilities such as:
- Secure role-based access controls
- Automated, non-editable audit trails
- Electronic signature functionality
- Validation support documentation
- Change control management
- Lot and batch traceability
- SOP version control
- Data backup and recovery procedures
As well, selecting solutions that are considered GAMP 5 Category 4 or better is imperative. Category 4 is considered a standard, out-of-the-box solution that can be configured to meet a pharmaceutical organization’s workflows and business requirements. GAMP 5 Category 5 is considered a customized solution. Homegrown solutions, as well as out-of-the-box solutions with custom code, are considered Category 5.
The right platform can significantly reduce compliance risk while improving operational efficiency.
Challenges with Non-Compliant Systems
Organizations that rely on spreadsheets, disconnected applications, or outdated software often encounter compliance risks such as:
- Missing documentation
- Incomplete or lack of audit trails
- Uncontrolled data changes
- Manual approval bottlenecks
- Difficulty retrieving historical records in a human readable format
- Inconsistent version control
These gaps can lead to costly remediation efforts, delayed product releases, or FDA findings during inspections.
Implementing a modern ERP platform designed for pharmaceutical operations can help organizations strengthen compliance while supporting scalable growth.
Real Scenarios Where Part 11 is Utilized in Pharmaceuticals
Pharmaceutical organizations rely on 21 CFR Part 11 compliance in ERP environments every day because regulated manufacturing and quality operations require secure, traceable electronic records and signatures.
For example, a biotech company running Phase 2 clinical trials may use an ERP system to manage raw material inventory, batch production records, quality control testing, and supplier approvals. When a production manager electronically signs off on a batch release or a quality assurance specialist approves a deviation investigation, the ERP system must ensure those electronic signatures are secure, time-stamped, and permanently linked to the corresponding records in accordance with FDA guidance.
Similarly, contract manufacturing organizations (CMOs) producing drug products for multiple pharmaceutical clients often depend on Part 11 compliant ERP platforms to maintain audit trails for formulation changes, equipment calibration records, and controlled document revisions.
The last example is based on a former employer of mine based in the New England area. When their product was created it was sent to Quality for review. In order for Quality to approve the product batch, they used their software solution to electronically sign off on these records. Part 11 for electronic signature was enforced in this instance. All audit trails were created and updated appropriately.
During FDA inspections, organizations are frequently asked to demonstrate a solution that shows who performed specific actions, when those actions occurred, and whether records were altered after approval. Without compliant electronic records and audit trails, companies risk warning letters, delayed product releases, or failed audits.
Final Thoughts
As the pharmaceutical industry continues moving toward digital operations, understanding FDA guidance around electronic records and electronic signatures is more important than ever. FDA 21 CFR Part 11 establishes the framework for ensuring that digital systems maintain the same trustworthiness and reliability as traditional paper documentation.
Pharmaceutical companies must ensure that their ERP and software platforms support secure audit trails, compliant electronic signatures, controlled access, and long-term record integrity. Failure to address these requirements can create significant compliance and operational risks.
.png)